Fierce Biotech

Bial bails after Parkinson’s fail, axing asset over phase 2 miss

Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary ...
WGN-TV

BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson's Disease Patients With a Pathogenic Variant in the Glucocerebrosidase ...

PORTO, Portugal, May 25, 2023 /PRNewswire/ -- BIAL - R&D Investments S.A (BIAL R&D), a subsidiary of BIAL Holding, S.A., today announced the dosing of the first patient in its Phase 2 clinical trial ...
KXAN

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

PORTO, Portugal, Jan. 7, 2025 /PRNewswire/ -- BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has ...